Investigation of a Novel Blood Test to Identify Breast Cancer (IDBC)
Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed. The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.
• Aged 30-75 years
• Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography
• Women with suspected Invasive Breast Cancer
• Individuals with an abnormal or suspicious mammogram
• Abnormal screening mammogram with suspected benign breast disease or proliferative changes